After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Crinetics Pharmaceuticals Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Crinetics Pharmaceuticals Inc is $2.91B. A total of 0.6 million shares were traded on the day, compared to an average of 1.02M shares.
In the most recent transaction, Pizzuti Dana sold 2,515 shares of CRNX for 34.20 per share on Mar 19 ’25. After the transaction, the Chief Med and Dev Officer now owns 72,233 company shares. In a previous transaction on Mar 19 ’25, Knight Jeff E. sold 7,162 shares at 34.20 per share. CRNX shares that Chief Operating Officer owns now total 87,491.
Among the insiders who sold shares, Betz Stephen F. disposed of 5,770 shares on Mar 19 ’25 at a per-share price of $34.20. This resulted in the Chief Scientific Officer holding 108,588 shares of CRNX after the transaction. In another insider transaction, Struthers Richard Scott sold 17,338 shares at $34.20 per share on Mar 19 ’25. Company shares held by the President & CEO now total 329,147.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, CRNX has a high of $62.53 and a low of $24.10.
As of this writing, CRNX has an earnings estimate of -$0.95 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of -$0.56 per share and a lower estimate of -$1.09.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CRNX’s latest balance sheet shows that the firm has $333.71M in Cash & Short Term Investments as of fiscal 2021. There were $3.07M in debt and $15.99M in liabilities at the time. Its Book Value Per Share was $14.26, while its Total Shareholder’s Equity was $331.94M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRNX is Buy with a score of 4.88.
